Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Inventory (2016 - 2025)

Historic Inventory for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $70.0 million.

  • Heron Therapeutics' Inventory rose 5239.39% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 5239.39%. This contributed to the annual value of $53.2 million for FY2024, which is 2624.08% up from last year.
  • Heron Therapeutics' Inventory amounted to $70.0 million in Q3 2025, which was up 5239.39% from $73.0 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Inventory peaked at $73.0 million during Q2 2025, and registered a low of $100000.0 during Q1 2024.
  • Over the past 5 years, Heron Therapeutics' median Inventory value was $48.4 million (recorded in 2021), while the average stood at $48.6 million.
  • As far as peak fluctuations go, Heron Therapeutics' Inventory crashed by 9980.79% in 2024, and later surged by 5683200.0% in 2025.
  • Heron Therapeutics' Inventory (Quarter) stood at $48.4 million in 2021, then rose by 12.8% to $54.6 million in 2022, then fell by 22.84% to $42.1 million in 2023, then rose by 26.24% to $53.2 million in 2024, then skyrocketed by 31.72% to $70.0 million in 2025.
  • Its Inventory stands at $70.0 million for Q3 2025, versus $73.0 million for Q2 2025 and $56.9 million for Q1 2025.